Facing Novel Challenges in Drug Discovery
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 January 2020) | Viewed by 54068
Special Issue Editors
Interests: multitarget anti-Alzheimer agents; hybrid compounds; cholinesterase inhibitors; amyloid anti-aggregating compounds; BACE-1 inhibitors; antiprotozoan compounds
Special Issues, Collections and Topics in MDPI journals
Interests: computational biology; molecular modeling; molecular simulations; drug design; multitarget compounds; neurodegeneration; antiviral compounds
Special Issues, Collections and Topics in MDPI journals
2. Pediatric Oncology Program, Institut de Recerca Sant Joan de Déu (IR SJD), Esplugues de Llobregat, Barcelona, Spain
3. Oncology Program, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III, Madrid, Spain
Interests: drug transporters; nucleoside analogs; anticancer therapy; antiviral therapy; mechanisms of drug action; nucleotide metabolism; oncogenesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Medicinal chemistry must continuously evolve to face the novel challenges that arise from the steady trickle of scientific breakthroughs. These advances have a profound impact on any phase of the drug discovery process, from the identification of novel biological targets or the molecular bases of drug action to the development of innovative technologies and disruptive approaches with the potential to speed up and reduce the costs associated with the development of new drugs.
This Special Issue is related to the “2nd Molecules Medicinal Chemistry Symposium (MMCS2019)”, which will be held 15–17 May, 2019, at the AXA Auditorium in Barcelona, Spain. The symposium will discuss current challenges in the drug discovery field, while reporting novel and revisited drug discovery approaches for particularly challenging diseases (cancer in this edition) and medicinal chemistry stories about recently implemented projects in target and hit identification, hit-to-lead optimization, tuning of physicochemical and pharmacokinetic properties, preclinical and clinical development, etc.
The symposium participants, as well as all researchers working in the field, are cordially invited to contribute original research papers, short communications, or reviews to this Special Issue of Molecules, reporting on recent innovative medicinal chemistry projects, particularly (but not only) on the design and development of novel anticancer drugs, protein degradation inducers, target-guided synthesis of bioactive compounds, and new targets and drug candidates. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on the journal website.
Prof. Dr. Diego Muñoz-Torrero
Prof. Dr. F. Javier Luque
Prof. Dr. Marçal Pastor-Anglada
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug discovery
- drug design
- drug synthesis
- cancer drug discovery
- protein degradation inducers
- target-guided synthesis
- novel biological targets
- novel drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.